Business News • MarketWire • Cesca Therapeutics Shareholders Reporting Group File 13D |
Cesca Therapeutics Shareholders Reporting Group File 13D |
|
|
Cesca Therapeutics Shareholders Reporting Group File 13D
RANCHO CORDOVA, CA--(Marketwired - Oct 27, 2014) - A Schedule 13D has been filed with the U.S. Securities and Exchange Commission on behalf of a group of shareholders in Cesca Therapeutics, a company formed by the merger earlier this year of leading cell-therapy device-maker ThermoGenesis Corp. and regenerative medicine clinical therapy company TotipotentRX, engaged in the research, development, and commercialization of point-of-care cell-based therapeutics for use in multiple chronic medical illnesses, including critical limb ischemia and acute myocardial infarction.
View More : http://www.marketwired.com/mw/release.do?id=1961322&sourceType=3
|
|
|